Systemic disease treatments are used to prolong survival and improve quality of life. Single-agent sequential cytotoxic therapy is preferred in the setting of metastatic breast cancer. Combination cytotoxic therapy is associated with a higher response rate, but toxicities are also increased, and it confers no survival benefit. Chemotherapy is used in patients with resistance to endocrine therapy or ER/PR-negative disease and a moderate or high disease burden.
Discover highlights from ASCO 2021 on the management of metastatic breast cancer here.
Learn more about the treatment and management of metastatic breast cancer.
Editor's Recommendations
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Fast Five Quiz: Are You Prepared to Confront Metastatic Breast Cancer? - Medscape - Dec 21, 2021.
Comments